Orgenesis Inc. (ORGS)

NASDAQ: ORGS · IEX Real-Time Price · USD
2.01
-0.08 (-3.73%)
Nov 29, 2022 3:18 PM EDT - Market open
-3.73%
Market Cap 53.39M
Revenue (ttm) 29.29M
Net Income (ttm) -5.78M
Shares Out 25.40M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,987
Open 2.18
Previous Close 2.09
Day's Range 2 - 2.18
52-Week Range 1.13 - 4.04
Beta 0.78
Analysts Buy
Price Target 9.18 (+356.3%)
Earnings Date Nov 10, 2022

About ORGS

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care f... [Read more]

Industry Biotechnology
Founded 2008
CEO Vered Caplan
Employees 151
Stock Exchange NASDAQ
Ticker Symbol ORGS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ORGS stock is "Buy." The 12-month stock price forecast is 9.18, which is an increase of 356.26% from the latest price.

Price Target
$9.18
(356.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022

Secures up to $50 Million of Funding from Metalmark Capital Partners  Expected to Accelerate Rollout of Point-of-Care Services

2 weeks ago - GlobeNewsWire

Orgenesis Schedules Third Quarter 2022 Business Update Conference Call

GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

2 weeks ago - GlobeNewsWire

Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-...

GERMANTOWN, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

3 weeks ago - GlobeNewsWire

Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022

Secures Funding from Metalmark Capital Partners to Drive Growth

3 months ago - GlobeNewsWire

Orgenesis Schedules Second Quarter 2022 Business Update Conference Call

GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

3 months ago - GlobeNewsWire

Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022

GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

6 months ago - GlobeNewsWire

Orgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder Grant

Focus is to Develop Cost-effective Production of Autologous Induced Pluripotent Stem Cells (iPSCs) using Microfluidic Technologies and Artificial Intelligence (AI) Focus is to Develop Cost-effective Pro...

6 months ago - GlobeNewsWire

Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update

Orgenesis to host conference call today at 12:00 PM ET Orgenesis to host conference call today at 12:00 PM ET

7 months ago - GlobeNewsWire

Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

GERMANTOWN, Md., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

10 months ago - GlobeNewsWire

Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell The...

Center will expand Orgenesis' Point of Care (POCare) Platform Capabilities in Maryland Center will expand Orgenesis' Point of Care (POCare) Platform Capabilities in Maryland

10 months ago - GlobeNewsWire

Orgenesis-Theracell Joint Venture Secures €32M Grant From Greek Government

Orgenesis Inc (NASDAQ: ORGS) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance.

1 year ago - Benzinga

Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year

Orgenesis to host conference call today at 8:30AM ET Orgenesis to host conference call today at 8:30AM ET

1 year ago - GlobeNewsWire

Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

1 year ago - GlobeNewsWire

Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

Goal to accelerate development, QC testing and manufacturing  of Orgenesis' cell and gene therapy platform

1 year ago - GlobeNewsWire

Orgenesis to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021

GERMANTOWN, MD / ACCESSWIRE / August 12, 2021 / Orgenesis Inc. (NASDAQ:ORGS), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be pr...

1 year ago - Accesswire

Orgenesis Schedules Second Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

1 year ago - GlobeNewsWire

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator...

Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (“SVF”) injections after rotator cuff surgery Investigator-initiated, rand...

1 year ago - GlobeNewsWire

Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd

GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

1 year ago - GlobeNewsWire

Orgenesis First Quarter 2021 Revenue Increases 400% to $9.4 Million Reflecting Initial Success of POCare Platform

Achieves operating profit for the first quarter of 2021

1 year ago - GlobeNewsWire

Orgenesis Schedules First Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

1 year ago - GlobeNewsWire

Orgenesis Enters into Collaboration Agreement with the Bambino Gesù Children's Hospital in Rome to Establish Point of...

GERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

1 year ago - GlobeNewsWire

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of ...

GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

1 year ago - GlobeNewsWire

Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call

GERMANTOWN, Md., March 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

1 year ago - GlobeNewsWire

Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform

Reports rapid advancement of therapeutic pipeline

2 years ago - GlobeNewsWire